Year: 2025
Type: article
Abstract: Psoriasis is a chronic, immune-mediated inflammatory dermatosis affecting 2 %-3 % of the global population, with significant psychosocial, metabolic and cardiovascular repercussions.Advances over the past five years have redefined diagnosis, now grounded in high-resolution digital dermoscopy, artificial intelligence and quality-of-life metrics, while therapy has evolved from phototherapy and classic immunosuppressants to target-specific biologic drugs (anti-IL-17, anti-IL-23) and small molecules such as the TYK-2 selective inhibitor deucravacitinib.Dermoscopy has demonstrated 92 % sensitivity and 87 % specificity in differentiating psoriatic plaques from other dermatoses.Phase III trials have shown that bimekizumab and risankizumab achieve PASI-100 rates exceeding 60 % at 52 weeks; deucravacitinib, as oral monotherapy, exhibited efficacy comparable to monoclonal antibodies with an acceptable safety profile.Deep-learning models integrated into teledermatology have expanded access to reference centers, especially in remote regions.Despite progress, challenges remain: the high cost of biologics, underrepresentation of high phototypes in image repositories, long-term safety gaps and access barriers in low-income countries.In conclusion, contemporary psoriasis management must be individualized, multidisciplinary and guided by objective severity scales, comorbidity assessment and rational selection of targeted therapies, underscoring the need for constant updating of national protocols.
Authors: Camilla Antunes Zanini, Mateus Sabaini Venazzi, Ian Caldeira Ruppen, André Cesar Leandro, Larissa da Rosa Piccoli, Tauane Cano Barreto, Emily Eduarda Hellmann, Ana Paula Mendes, Priscila De Oliveira Barros, Sarila Hali Kloster Lopes, Lara Beatriz Dallaqua Bitiati, Ana Carolina Langendyk Rodrigues, Maria Clara Costa Calvo
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4412573188